Einstein-Montefiore Clinical and Translational Science Award Hub

哈罗德和穆里尔布洛克临床和转化研究所（ICTR）在阿尔伯特爱因斯坦 医学院和蒙蒂菲奥里医疗中心作为我们的CTSA计划的家。的愿景 卢旺达问题国际法庭的任务是改善布朗克斯和其他遭受不成比例和不公正待遇的社区的健康状况 从健康状况不佳和过早死亡，通过加速生物医学发现转化为有效的， 可持续的疾病预防和治疗战略。卢旺达问题国际法庭成立于2007年， 翻译研究（CTR）在爱因斯坦和蒙蒂菲奥里通过创造一个强大的研究环境;重新- 工程CTR流程;整合研究和医疗保健;以及发展强大的社区 关系。卢旺达问题国际法庭的主题是“在布朗克斯及以外地区建立桥梁”，强调了 弥合我们的研究人员，卫生系统领导者，临床医生，患者，社区和CTSA之间的差距 促进转化科学和健康公平的合作伙伴。卢旺达问题国际法庭的具体目标是： 创新将提高转化研究的效率和有效性。我们将支持和资助 具有克服重大CTR障碍和卫生不公平的高潜力的研究;创建方法和 信息学转化科学创新;改进CTR操作，加强传播和 执行战略。(2)让社区、患者和其他合作伙伴尽早参与， 翻译过程我们新的社区和利益相关者参与研究模块将改变我们的 学习健康体系建设成为“学习健康研究共同体”，促进积极、持续的双向发展 与社区、患者和其他合作伙伴的沟通;促进研究，以确定和减轻社会 健康的决定因素，并加强目标人群对循证方案的吸收。(3)开发和 实施最先进的临床研究和信息学资源和服务，以提高严谨性，安全性， CTR的效率、有效性和普遍性。(4)培训，发展，并保持一个熟练的，多学科的， 和多样化的翻译队伍，以支持和领导高质量的研究与新的培训和途径 项目旨在确保历史上被排斥群体的成员参与CTR并成为研究领导者。（五） 与其他CTSA中心和CTSA联盟合作，加快CTR并快速响应紧急公共 健康需求。我们的目标与新的CTSA方案目标一致，将使卢旺达问题国际法庭能够最大限度地 有助于国家合作CTSA财团的集体努力，提供更多的治疗， 在布朗克斯和更远的地方，

The Harold and Muriel Block Institute for Clinical and Translational Research (ICTR) at the Albert Einstein College of Medicine and Montefiore Medical Center serves as the home of our CTSA program. The vision of the ICTR is to improve the health of the Bronx, and other communities that disproportionately and unjustly suffer from poor heath and premature death, by accelerating the translation of biomedical discoveries into effective and sustainable disease prevention and treatment strategies. Created in 2007, the ICTR has transformed clinical and translational research (CTR) throughout Einstein and Montefiore by creating a robust research environment; re- engineering CTR processes; integrating research and healthcare; and developing strong community relationships. The ICTR theme of “Building Bridges in the Bronx and Beyond” underscores the importance of bridging gaps between our researchers, health system leaders, clinicians, patients, communities, and CTSA partners to advance translational science and health equity. The specific aims of the ICTR are to: (1) Catalyze innovations that will enhance the efficiency and effectiveness of translational research. We will support and fund studies with high potential to overcome major CTR roadblocks and health inequities; create methodological and informatics translational science innovations; improve CTR operations, and enhance dissemination and implementation strategies. (2) Engage communities, patients, and other partners early and throughout the translational process. Our new Community and Stakeholder Engagement Research module will transform our learning health system into a “learning health research community”; promote active and continuous bidirectional communication with communities, patients and other partners; facilitate research to identify and mitigate social determinants of health, and enhance uptake of evidence-based programs by target populations. (3) Develop and implement state-of-the-art clinical research and informatics resources and services to improve the rigor, safety, efficiency, effectiveness, and generalizability of CTR. (4) Train, develop, and maintain a skilled, multidisciplinary, and diverse translational workforce to support and lead high quality research with new training and pathway programs to ensure members of historically excluded groups engage in CTR and become research leaders. (5) Partner with other CTSA hubs and the CTSA consortium to accelerate CTR and rapidly respond to urgent public health needs. Our aims are aligned with the new CTSA program goals and will enable the ICTR to maximally contribute to the collective efforts of the national collaborative CTSA consortium to deliver more treatments to more patients more quickly in the Bronx and beyond.